Research Article

Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents

Table 2

Proinflammatory cytokine levels in plasma. At 2 weeks, plasma levels of IL-13, IL-17, KC, and TNF- were increased in the CAWS group, compared to negative control group. KC was suppressed by all the drugs tested, and IL-17 was reduced by etanercept and methylprednisolone treatment. At 4 weeks, the increased levels of IL-13, IL-17, and TNF-α persisted in the CAWS group with an increase in IL-6 and IL-12 levels. Etanercept significantly suppressed the levels of IL-6, IL-12, IL-13, and TNF- , whereas cyclosporine-A reduced IL-13, IL-17, and TNF-α levels.

ConCAWSIVIGECMPCsA

IL-13 142 ± 69.2 277 ± 98.8#423 ± 333376 ± 361 214 ± 97.1256 ± 138
2 weeksIL-17 7.71 ± 3.78 44 ± 17.7#22.5 ± 14.5 11.3 ± 9.23* 8.03 ± 4.62*12.6 ± 2.88
KC 24.4 ± 31.4 113 ± 61.5# 4.83 ± 1.49* 9.54 ± 6.68* 7.47 ± 0.78* 9.77 ± 5.14*
TNF-α 152 ± 54.9 276 ± 75.1#253 ± 251 217 ± 49.3205 ± 118227 ± 163

IL-6 20.1 ± 18.643.7 ± 6.72# 29.7 ± 8.6* 16.8 ± 7.63**66.5 ± 46.941.2 ± 14.9
IL-12 353 ± 155577 ± 167#458 ± 157 253 ± 104* 253 ± 70*495 ± 298
4 weeksIL-13 170 ± 64.6328 ± 103#330 ± 164 188 ± 84.3* 382 ± 82.9 161 ± 61*
IL-17 9.7 ± 4.0734.5 ± 10.2#28.3 ± 19.3 26 ± 18.261.9 ± 36.2 11.1 ± 8.76*
TNF-α 166 ± 56.7525 ± 175#301 ± 112 247 ± 78.2*346 ± 111 240 ± 90*

versus Con.
versus CAWS.
versus CAWS.